ABUS Arbutus Biopharma Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1447028 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,142.6%
TTM net income YoY620.2%
TTM EPS YoY587.0%
Revenue 3-yr CAGR101.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin81.1%
Net margin121.2%
FCF margin—
EBITDA margin81.1%
Returns
ROE269.6%
ROA100.6%
ROIC (approx.)—
Asset turnover0.83x
Leverage & solvency
Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.40x
Interest coverage2,299.38x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $14.08M | $6.17M | $18.14M | $39.02M | $10.99M |
| R&D expense | $25.24M | $54.04M | $73.70M | $84.41M | $65.50M |
| SG&A expense | $15.89M | $22.11M | $22.48M | $17.83M | $17.14M |
| Operating income | -$38.16M | -$76.32M | -$78.10M | -$65.46M | -$73.52M |
| Interest expense | $97,000 | $137,000 | $459,000 | $1.73M | $2.86M |
| Pretax income | $11.95M | -$1.67M | -$14.80M | -$28.70M | -$7.70M |
| Income tax | $0 | $0 | $0 | $4.44M | $0 |
| Net income | -$33.50M | -$69.92M | -$72.85M | -$69.46M | -$76.25M |
| EBITDA | -$37.80M | -$74.94M | -$76.70M | -$64.03M | -$71.77M |
| EPS (basic) | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
| EPS (diluted) | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
| Weighted avg. shares (diluted) | 191.60M | 185.61M | 165.96M | 150.94M | 106.24M |
| Balance sheet | |||||
| Cash & equivalents | $18.01M | $36.33M | $26.29M | $30.78M | $109.28M |
| Short-term investments | $73.46M | $86.29M | $99.72M | $116.14M | $46.03M |
| Receivables | $1.45M | $2.41M | $1.78M | $1.35M | $899,000 |
| Current assets | $94.46M | $127.32M | $132.03M | $151.14M | $160.66M |
| PP&E, net | $32,000 | $3.31M | $4.67M | $5.07M | $5.98M |
| Total assets | $94.62M | $131.71M | $144.40M | $195.42M | $204.49M |
| Current liabilities | $6.01M | $15.62M | $22.49M | $32.86M | $11.22M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $18.04M | $34.34M | $38.38M | $58.57M | $35.05M |
| Shareholders' equity | $76.58M | $97.37M | $106.02M | $136.85M | $169.44M |
| Net debt | -$18.01M | -$36.33M | -$26.29M | -$30.78M | -$109.28M |
| Shares outstanding | 192.53M | 189.96M | 169.87M | 157.46M | 144.99M |
| Cash flow statement | |||||
| Operating cash flow | -$39.64M | -$64.85M | -$85.94M | -$35.36M | -$67.53M |
| Capital expenditure | $0 | $182,000 | $1.01M | $512,000 | $809,000 |
| Free cash flow | -$39.64M | -$65.03M | -$86.94M | -$35.87M | -$68.34M |
| Investing cash flow | $15.58M | $22.95M | $50.77M | -$74.94M | -$12.68M |
| Financing cash flow | $5.72M | $52.00M | $30.65M | $31.81M | $137.24M |
| Depreciation & amortization | $363,000 | $1.38M | $1.40M | $1.43M | $1.75M |
| Stock-based compensation | $6.95M | $8.99M | $9.30M | $7.18M | $6.42M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.